Clinical and Molecular Phenotyping in Scleromyxedema Pretreatment and Posttreatment With Intravenous Immunoglobulin.
Christopher A MecoliC Conover TalbotAndrea FavaChristopher CheadleFrancesco BoinFredrick M WigleyLaura K HummersPublished in: Arthritis care & research (2020)
This open-label study further supports the evidence that patients with SMX respond both objectively and subjectively to IVIG therapy. Biologic studies suggest a role for T lymphocytes in the pathogenesis of the disease and reveal the potential significance of TGFβ and interferon pathways.
Keyphrases
- open label
- rheumatoid arthritis
- physical activity
- clinical trial
- high throughput
- transforming growth factor
- dendritic cells
- randomized controlled trial
- genome wide
- single cell
- stem cells
- immune response
- phase ii
- radiation therapy
- gene expression
- human health
- climate change
- epithelial mesenchymal transition
- cell therapy